targeted drug delivery

AIS Healthcare is a healthcare company with two divisions: Advanced Infusion Care (AIC), which offers in-home immunoglobulin (Ig) and Alpha-1 therapy and access to FDA-approved treatments in its infusion centers, and Targeted Drug Delivery (TDD), which provides patient-specific compounded medications and services for individuals with surgically implanted intrathecal infusion pumps through two 503A compounding pharmacies. It is dually accredited by URAC and the Accreditation Commission for Health Care and employs more than 300 nurses.

503A compounding pharmacyhome infusion nursinginfusion centersterminal sterilization

AptamiR Therapeutics, Inc. is a US modular biotechnology company executing the pre-clinical development phase of its targeting OligoNucleotide Therapeutic (ONT) drug candidates. It develops microRNA-based therapeutics using a One Drug-Multiple Targets concept, with projects targeting cardiometabolic disorders (obesity, diabetes, MAFLD/MASH) and epithelial ovarian cancer.

in vitro testingin vivo testingmicroRNA-based therapeuticspre-clinical drug developmentvirtual outsourced drug research and development

Basic Home Infusion (BHI) is a national home infusion company with 35+ years of experience providing infusion and intrathecal therapy services in patients' homes. BHI offers targeted drug delivery (TDD) and intrathecal pump management, specialty pharmacies, home-visit nurses, and a 24/7 patient care center, coordinating care among physicians, provider staff, and patients nationwide.

24/7 patient care centerhome infusionhome-visit nursingintrathecal pump managementpatient care managementsterile compounding

BioSyntex Laboratories, LLC is a small, woman-owned drug discovery and design company developing nanotechnology-driven pharmaceuticals and hybrid therapeutics that combine biologically derived carriers such as vesicles, exosomes, and peptide ligands with small molecule payloads. Its platform targets neuroinflammation and infectious disease along the gut-brain axis, with delivery routes optimized for oral, intranasal, and vesicle-enabled CNS penetration. The company is advancing multiple drug candidates toward IND-enabling studies and welcomes collaborati

drug designdrug discoverynano-medicinepharmaceutical research

Exvade is an oncology-focused company developing the Tumor Monorail Device, which uses bio-inspired cues to guide invasive brain tumor cells into a small, accessible reservoir where they can be safely removed and analyzed. The company is conducting a First-in-Human study of the device at the Preston Robert Tisch Brain Tumor Center at Duke University to evaluate its safety.

clinical trialsprecision tumor removalreal-time tissue analysis

ForCast Orthopedics is a development-stage company focused on modernizing care for complex orthopedic infections, pioneering targeted antibiotic therapy and localized drug delivery for periprosthetic joint infection (PJI) following joint replacement surgery. Its proprietary platform automates a treatment method demonstrated in clinical research to achieve superior patient outcomes versus the standard of care.

localized treatment of PJIpharmaceutical developmentproduct development